Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours

Endometrial carcinoma, the most common gynaecological cancer, develops from endometrial epithelium which is composed of secretory and ciliated cells. Pathologic classification is unreliable and there is a need for prognostic tools. We used single cell sequencing to study organoid model systems derived from normal endometrial endometrium to discover novel markers specific for endometrial ciliated or secretory cells. A marker of secretory cells (MPST) and several markers of ciliated cells (FAM92B, WDR16, and DYDC2) were validated by immunohistochemistry on organoids and tissue sections. We performed single cell sequencing on endometrial and ovarian tumours and found both secretory‐like and ciliated‐like tumour cells. We found that ciliated cell markers (DYDC2, CTH, FOXJ1, and p73) and the secretory cell marker MPST were expressed in endometrial tumours and positively correlated with disease‐specific and overall survival of endometrial cancer patients. These findings suggest that expression of differentiation markers in tumours correlates with less aggressive disease, as would be expected for tumours that retain differentiation capacity, albeit cryptic in the case of ciliated cells. These markers could be used to improve the risk stratification of endometrial cancer patients, thereby improving their management. We further assessed whether consideration of MPST expression could refine the ProMiSE molecular classification system for endometrial tumours. We found that higher expression levels of MPST could be used to refine stratification of three of the four ProMiSE molecular subgroups, and that any level of MPST expression was able to significantly refine risk stratification of the copy number high subgroup which has the worst prognosis. Taken together, this shows that single cell sequencing of putative cells of origin has the potential to uncover novel biomarkers that could be used to guide management of cancers. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Fabian J Theis,et al.  Generalizing RNA velocity to transient cell states through dynamical modeling , 2019, Nature Biotechnology.

[2]  Kieran R. Campbell,et al.  Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling , 2019, Nature Methods.

[3]  S. Bandyopadhyay,et al.  Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. , 2019, Gynecologic oncology.

[4]  C. Yau,et al.  The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells , 2019, bioRxiv.

[5]  S. Leung,et al.  Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction , 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  D. Huntsman,et al.  Oncogenic Mutations in Histologically Normal Endometrium: The New Normal? , 2019, bioRxiv.

[7]  M. Köbel,et al.  Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[8]  M. Stratton,et al.  The mutational landscape of normal human endometrial epithelium , 2018, bioRxiv.

[9]  D. Levine,et al.  Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma , 2018, bioRxiv.

[10]  Anthony Liew,et al.  Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq , 2018, PloS one.

[11]  Dongxi Xiang,et al.  Long-term organoid culture reveals enrichment of organoid-forming epithelial cells in the fimbrial portion of mouse fallopian tube. , 2018, Stem cell research.

[12]  Erik Sundström,et al.  RNA velocity of single cells , 2018, Nature.

[13]  S. Quake,et al.  Single cell RNAseq provides a molecular and cellular cartography of changes to the human endometrium through the menstrual cycle , 2018, bioRxiv.

[14]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Desai,et al.  A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours , 2018, Investigational New Drugs.

[16]  Lisa V. Hampson,et al.  A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma , 2018, British Journal of Cancer.

[17]  N. Nagahara.  Multiple role of 3‐mercaptopyruvate sulfurtransferase: antioxidative function, H2S and polysulfide production and possible SOx production , 2018, British journal of pharmacology.

[18]  J. Soria,et al.  First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Samuel Leung,et al.  Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.

[20]  D. Lefer,et al.  3-Mercaptopyruvate sulfurtransferase produces potential redox regulators cysteine- and glutathione-persulfide (Cys-SSH and GSSH) together with signaling molecules H2S2, H2S3 and H2S , 2017, Scientific Reports.

[21]  P. Tanwar,et al.  In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells , 2017, Development.

[22]  Edda Klipp,et al.  Estimation of immune cell content in tumour tissue using single-cell RNA-seq data , 2017, Nature Communications.

[23]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[24]  G. Curigliano,et al.  Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer , 2016, Oncotarget.

[25]  Gregg B. Morin,et al.  Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research , 2016, Scientific Reports.

[26]  A. Talhouk,et al.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. , 2016, Gynecologic oncology.

[27]  Valentina Paloschi,et al.  Phenotypic Modulation of Smooth Muscle Cells in Atherosclerosis Is Associated With Downregulation of LMOD1, SYNPO2, PDLIM7, PLN, and SYNM , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[28]  K. Takemaru,et al.  BAR Domain-Containing FAM92 Proteins Interact with Chibby1 To Facilitate Ciliogenesis , 2016, Molecular and Cellular Biology.

[29]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[30]  A. Study.  Evidence of a genetic link between endometriosis and ovarian cancer. , 2016 .

[31]  A. Berchuck,et al.  Evidence of a genetic link between endometriosis and ovarian cancer. , 2016, Fertility and sterility.

[32]  H. Mollenkopf,et al.  The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids , 2015, Nature Communications.

[33]  A. Whittemore,et al.  Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. , 2015, Human molecular genetics.

[34]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[35]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[36]  P. Pollock,et al.  Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.

[37]  M. Chun,et al.  Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria , 2015, Journal of gynecologic oncology.

[38]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[39]  T. Bosse,et al.  High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. , 2014, Gynecologic oncology.

[40]  Mélanie Gadelorge,et al.  CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment , 2013, Journal of cellular and molecular medicine.

[41]  S. Leung,et al.  Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.

[42]  C Blake Gilks,et al.  Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.

[43]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[44]  R. Soslow.  High‐grade endometrial carcinomas – strategies for typing , 2013, Histopathology.

[45]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[46]  Douglas G. Altman,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[47]  T. Herzog,et al.  Contemporary management of endometrial cancer , 2012, The Lancet.

[48]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[49]  F. Falciani,et al.  Identification and angiogenic role of the novel tumor endothelial marker CLEC14A , 2012, Oncogene.

[50]  M. Carey,et al.  Are Uterine Risk Factors More Important Than Nodal Status in Predicting Survival in Endometrial Cancer? , 2009, Obstetrics and gynecology.

[51]  Xiaozhong Peng,et al.  Crystal structure of the C-terminal domain of human DPY-30-like protein: A component of the histone methyltransferase complex. , 2009, Journal of molecular biology.

[52]  D. Melton,et al.  Notch signaling promotes airway mucous metaplasia and inhibits alveolar development , 2009, Development.

[53]  M. Castiglione,et al.  Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Andrea Mariani,et al.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. , 2008, Gynecologic oncology.

[55]  K. Wiesmüller,et al.  Biosynthesis of Wdr16, a marker protein for kinocilia‐bearing cells, starts at the time of kinocilia formation in rat, and wdr16 gene knockdown causes hydrocephalus in zebrafish 1 , 2006, Journal of neurochemistry.

[56]  F. Sotgia,et al.  A Novel Role for Caveolin-1 in B Lymphocyte Function and the Development of Thymus-Independent Immune Responses , 2006, Cell cycle.

[57]  A. Rawstron.  Immunophenotyping of Plasma Cells , 2006, Current protocols in cytometry.

[58]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[59]  S. Brody,et al.  Role of f-box factor foxj1 in differentiation of ciliated airway epithelial cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[60]  B. Gomperts,et al.  Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells , 2004, Journal of Cell Science.

[61]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[62]  S. Brody,et al.  Foxj1 is required for apical localization of ezrin in airway epithelial cells , 2003, Journal of Cell Science.

[63]  J. Fanning.  Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. , 2001, Gynecologic oncology.

[64]  I. More,et al.  The role of oestrogen in the control of ciliated cells of the human endometrium. , 1976, Journal of reproduction and fertility.

[65]  I. More,et al.  The cyclical variation in the percentage of ciliated cells in the normal human endometrium. , 1975, Journal of reproduction and fertility.

[66]  J. W. Roddick,et al.  Ciliated endometrial cells. , 1968, American journal of obstetrics and gynecology.

[67]  E. Schueller.  Ciliated epithelia of the human uterine mucosa. , 1968, Obstetrics and gynecology.

[68]  E. Davis.  CARCINOMA OF THE CORPUS UTERI. , 1964, American journal of obstetrics and gynecology.

[69]  S. D. Mearses.  ENDOMETRIAL CARCINOMA. , 1963, The Medical journal of Malaya.

[70]  RosaGFP SPCCre.  Notch signaling promotes airway mucous metaplasia and inhibits alveolar development , 2022 .